Tuberculosis Therapeutics Market Opportunity, and Forecasts Report 2025-2030: Next-Gen Drug Development Demands, Cost Efficiency, Regulatory Agility, and Strategic Partnerships Influence on Growth
The Tuberculosis Therapeutics Market is driven by rising drug-resistant TB and persistent global demand. Opportunities include developing innovative, cost-effective TB drugs with shorter, more effective regimens. Companies can gain a competitive edge through strategic collaborations and navigating regulatory barriers.
Tuberculosis Therapeutics Market
Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The Tuberculosis Therapeutics Market was valued at USD 2.18 Billion in 2024, and is expected to reach USD 2.94 Billion by 2030, rising at a CAGR of 5.05%
Positioned as a crucial segment within infectious disease treatment, this market benefits from persistent global demand, especially due to the rising incidence of drug-resistant TB. Despite its historically low profit margins, the TB therapeutics space offers significant public health value and long-term commercial potential. Governments, health agencies, and pharmaceutical firms are increasingly prioritizing the development of innovative TB treatments, supported by consistent global case numbers and substantial funding from donors and public institutions.
With next-generation drug development - particularly in second-line therapies - on the rise, companies that can balance cost-effectiveness, navigate regulatory landscapes, and build strategic collaborations are well-placed to secure a sustainable competitive edge.
Key Market Drivers
High Global Burden of TuberculosisThe global tuberculosis (TB) burden remains a primary driver of market expansion. WHO data indicates that 10.8 million people contracted TB in 2023, up from 10.7 million in 2022, highlighting a rising trend. This sustained prevalence ensures ongoing demand for both first-line and second-line TB therapies, reinforcing the market's stability.
For pharmaceutical companies, this represents a significant opportunity to scale drug portfolios and foster collaborations with public health organizations. The high incidence, particularly in regions with limited healthcare infrastructure, underscores the necessity for scalable treatment solutions, positioning the TB therapeutics market as a reliable avenue for both healthcare impact and commercial returns.Key Market Challenges
Inadequate Funding and Limited Commercial Incentives for Drug DevelopmentThe concentration of TB cases in low- and middle-income countries often means that treatment relies on public funding and donor support rather than private investment. This results in limited profitability, discouraging pharmaceutical companies from prioritizing TB drug development. With constrained pricing models, complex regulatory pathways, and minimal patent protection, the return on investment for TB drugs is typically low.
Further, the extended timelines of clinical trials and dependency on external funding inhibit innovation. Without enhanced incentives such as co-development frameworks or market guarantees, TB therapeutics are likely to lag behind other disease areas in terms of pharmaceutical innovation.Key Market Trends
Shift Toward Shorter, More Effective Treatment RegimensThere is a growing emphasis on developing shorter, more tolerable TB treatment regimens to improve adherence and outcomes. Novel combinations, such as the 6-month BPaL regimen, are transforming the landscape by reducing the treatment burden compared to traditional 18-24-month protocols. Supported by WHO endorsements and donor-funded initiatives, these advancements are generating increased interest in next-generation therapies. Pharmaceutical companies capable of innovating in fixed-dose combinations and new drug mechanisms stand to benefit from this shift, as these regimens often command higher per-patient value due to better efficacy, reduced side effects, and enhanced patient compliance.
Key Attributes:
Report Attribute
Details
No. of Pages
180
Forecast Period
2024 - 2030
Estimated Market Value (USD) in 2024
$2.18 Billion
Forecasted Market Value (USD) by 2030
$2.94 Billion
Compound Annual Growth Rate
5.0%
Regions Covered
Global
Report Scope
Key Market Players
AstraZeneca PLC
Johnson & Johnson Services, Inc.
Eli Lilly and Company
Mylan Inc.
Teva Pharmaceutical Industries Ltd
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd
Pfizer Inc.
Tuberculosis Therapeutics Market, By Disease Type:
Active TB
Latent TB
Tuberculosis Therapeutics Market, By Therapy:
First-Line Therapy
Second-Line Therapy
Tuberculosis Therapeutics Market, By Route of Administration:
Oral
Parenteral
Others
Tuberculosis Therapeutics Market, By Dosage Form:
Tablets
Capsules
Injection
Others
Tuberculosis Therapeutics Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Tuberculosis Therapeutics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
For more information about this report visit https://www.researchandmarkets.com/r/m41o34
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Tuberculosis Therapeutics Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
BrainDefender Research Announces Launch of New Cognitive Support Formula for Adults
Plant-Based Supplement Includes Five Individual Ingredients Studied for Their Role in Supporting Memory and Focus Denver, June 06, 2025 (GLOBE NEWSWIRE) -- BrainDefender Research today announced the launch of , a new cognitive wellness formula developed to support focus, mental clarity, and memory in adults. Manufactured in a GMP-certified facility in the United States, the product is designed for individuals seeking to maintain healthy cognitive function through natural, plant-based supplementation. The new formula features a combination of Ginkgo Biloba, Bacopa Monnieri, Huperzine-A, Phosphatidylserine, and N-Acetyl-L-Carnitine—ingredients that have each been individually studied for their potential roles in brain function. BrainDefender Research emphasizes that the supplement is intended for use as part of a wellness routine to support cognitive performance and healthy aging. 'Consumer interest in natural brain support has grown significantly in recent years,' said a spokesperson for BrainDefender Research. 'We developed this product to offer adults a well-rounded option for supporting mental clarity, focus, and memory performance using recognizable, research-supported ingredients.' The company recommends consistent daily use over a 90-day period for best results and offers a 60-day refund policy for customer satisfaction. The product is available for purchase in 30-day, 90-day, and 180-day supply options to accommodate individual wellness goals. AvailabilityBrainDefender Memory Support Supplement can be ordered directly through the company's official website and is also offered via the ClickBank platform. Domestic orders are typically delivered within 5–7 business days, while international shipping may take 10–12 business days. About BrainDefender ResearchBrainDefender Research is a U.S.-based wellness company focused on the development of cognitive support supplements using plant-based ingredients. All products are manufactured in GMP-certified facilities to ensure quality and safety in every batch. DisclaimerThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Individuals should consult a licensed healthcare provider before beginning any new supplement routine, especially if taking medications or managing a medical condition. Media Contact Email: support@ Phone: (855) 473-4405 CONTACT: Email: support@ Phone: (855) 473-4405Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Japan Smaller Capitalization Fund, Inc. Announces Initiatives to Enhance Shareholder Value
10% Annual Rate Level Distribution Policy Conditional Tender Offer for 10% of Outstanding Shares NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Japan Smaller Capitalization Fund, Inc. (the 'Fund') (NYSE: JOF) today announced that its Board of Directors (the 'Board') has approved two initiatives aimed at addressing the Fund's trading discount. These initiatives include a level distribution plan and a conditional tender offer. The Board believes these actions reflect the Fund's ongoing commitment to enhancing shareholder value, delivering competitive performance, and providing consistent distributions to long-term shareholders. The plan (the 'Plan') includes (i) implementation of a Level Distribution Plan (the 'LDP') to pay monthly distributions at a 10% annual rate to provide more of the Fund's total return in the form of distributions, and (ii) a conditional tender offer (the 'CTO') of 10% of its outstanding shares. Level Distribution Plan The Board has approved a Level Distribution Plan under which the Fund will pay monthly distributions at an annualized rate of 10% of the Fund's Net Asset Value ('NAV') as of May 31, 2025. The Fund is declaring a monthly distribution of $0.0887 per common share for each of July, August and September. The Fund's distribution details are as follows: Record Date Ex-Dividend Date Payment Date Distribution Amount July 15, 2025 July 15, 2025 July 31, 2025 $ 0.0887 August 15, 2025 August 15, 2025 August 29, 2025 $ 0.0887 September 15, 2025 September 15, 2025 September 30, 2025 $ 0.0887 The LDP is intended to provide shareholders with a constant, though not guaranteed, fixed rate of distribution each month. In approving the LDP, the Board considered, among other factors, the potential impact of the LDP as a tool to narrow the discount to NAV at which the Fund's shares have historically traded, the Fund's ability to sustain the LDP, and the possibility that making regular distributions could enhance liquidity for common shareholders and potentially attract new investors. Distributions will be made primarily in cash but under the Fund's dividend-reinvestment plan, distributions will be made in Fund shares unless a shareholder has elected to receive cash. Shares held with a broker-dealer will receive distributions in cash. Under the LDP, distributions may be derived from any combination of: (i) net investment income, (ii) realized capital gains, and/or (iii) a return of shareholder capital. The actual composition for each fiscal year will be reported to shareholders on Form 1099-DIV after year-end. Estimates provided in any monthly notice or in this press release are not intended for tax-reporting purposes and should not be relied upon as such. The Fund cannot predict what effect, if any, the LDP will have on the market price of its shares, or whether such market price will trade at a narrower or wider discount to NAV compared to levels prior to the Plan's adoption. Conditional Tender Offer In addition to the LDP, the Board approved a Conditional Tender Offer. The Fund will launch a tender offer for 10% of its outstanding shares, provided that the Fund's shares trade at an average daily market price discount of 9% or greater to NAV during the nine-month measurement period beginning on July 1, 2025 and ending on March 31, 2026 (the 'Measurement Period'). At the end of the Measurement Period, the Fund will announce additional details about the tender offer, as appropriate. In approving the CTO, the Board considered, among other factors, that a rules-based approach gives shareholders clear, time-bounded relief if the discount persists, the complementary nature of the CTO with the LDP, the reinforcement of the Fund's commitment to shareholder-friendly capital management, and the offer of meaningful liquidity to shareholders. There can be no guarantee that these benefits will occur or that any improvement will continue. The Board may terminate or modify the parameters of the Plan at any time without prior notice to the Fund's shareholders if circumstances warrant. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund's common shares. To assist the Board in its evaluation of the LDP, the CTO, and other potential corporate actions, the Fund engaged an unaffiliated financial adviser with significant closed-end fund expertise. The professional fees associated with this limited-duration engagement will be borne by the Fund and are expected to result in a short-term increase in the Fund's expense ratio. Investment Outlook While overall earnings growth is expected to be higher in the United States, the Japanese market is expected to have growth rates comparable to the United States in most sectors besides the Industrials sector. Nomura Asset Management Co., Ltd. ('NAM') believes Return on Equity ('ROE') is on an upward trend in Japan, supported by improvements in profit margins and revenue growth. NAM expects share buybacks and dividend increases will continue to raise the financial leverage. With ongoing corporate reforms, there is a potential for ROE to rise further. Japan remains one of the most attractive markets for individual stock selection due to a lack of coverage. Continued Focus on Long-Term Value Today's announcement represents the Fund's objective to deliver competitive performance and stable distributions to shareholders. The Board and Nomura Asset Management U.S.A. Inc. ('NAM-U.S.A.') remain committed to delivering long-term value creation and addressing the interests of our shareholders. About the Fund The Fund invests primarily in the securities of smaller capitalization companies in Japan and is designed for investors seeking long-term capital appreciation. The Manager of the Fund is NAM-U.S.A., which is based in New York. NAM-U.S.A. is a subsidiary of NAM, which is one of the largest investment advisory companies in Japan in terms of assets under management and serves as the investment adviser to the Fund. Forward Looking Statements Certain information discussed in this press release may constitute forward-looking statements within the meaning of U.S. federal securities laws. Although the Fund and NAM-U.S.A. believe that the expectations reflected in such forward-looking statements are based on reasonable assumptions, the Fund and NAM-U.S.A. can give no assurance that their expectations will be achieved. Forward-looking information is subject to certain risks, trends, and uncertainties that could cause actual results to differ materially from those projected. Contact: Maria Premole 1-800-833-0018 JOFInvestorRelations@ in to access your portfolio
Yahoo
an hour ago
- Yahoo
AI Insider Blows the Lid Off Musk's Secret AI Operation
BALTIMORE, June 06, 2025 (GLOBE NEWSWIRE) -- A mysterious AI complex in Memphis is now being called the most powerful system of its kind — and it wasn't supposed to be public knowledge. In a newly released briefing, bestselling author and tech expert James Altucher reveals the details of a covert AI operation led by Elon Musk that, until now, has gone almost entirely unreported. Known as Project Colossus, the facility was built by Musk's AI company, xAI, and is allegedly housing the highest-density AI computing power in the Western Hemisphere. 'The AI Mothership' Altucher says the project has quietly surpassed every major tech firm in the race for AI dominance — including OpenAI, Microsoft, Meta, and even Nvidia. 'Elon Musk has created the AI mothership… an innovation of such enormous proportion… that he has already surpassed all the leading AI developers.' He adds that the complex is powered by 200,000 high-performance AI chips — and growing. 'Making it the most advanced AI facility known to man.' Buried in a Warehouse. Unleashed by Policy. According to Altucher, the project only became possible after a specific presidential action early in Trump's second term. 'In one of his FIRST acts as President… Donald Trump overturned Executive Order #14110.' That order had previously restricted advanced AI development in the name of safety and oversight. Its removal, Altucher says, opened the floodgates. Not a Tool. A Turning Point. Altucher warns that this isn't just about AI doing tasks faster. This is a leap into self-operating systems that think, react, and solve. 'AI 2.0… gives that knowledge to intelligent machines that I believe will solve our problems for us.' He claims a major update to Colossus — scheduled before July 1 — could mark the moment America enters a new technological era. About James Altucher James Altucher is a computer scientist, entrepreneur, and bestselling author with four decades of experience in artificial intelligence and innovation. His past work includes contributions to IBM's Deep Blue supercomputer and the early development of AI-driven market systems. His recent briefings focus on the intersection of AI, secrecy, and national acceleration. Media Contact:Derek WarrenPublic Relations ManagerParadigm Press GroupEmail: dwarren@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
